SCOPUS 정보 검색 플랫폼

Science Translational Medicine

Volumn 6, Issue 255, 2014, Pages

Genomic complexity: A call to action

(2) Hait, William N a Levine, Arnold J b,c

a Janssen Research and Development (United States)

b INSTITUTE FOR ADVANCED STUDY (United States)

c RUTGERS CANCER INSTITUTE OF NEW JERSEY (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; BOSUTINIB; CABOZANTINIB; CETUXIMAB; CRIZOTINIB; CYCLOOXYGENASE 2 INHIBITOR; DABRAFENIB; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; NILOTINIB; OBINUTUZUMAB; OFATUMUMAB; PANITUMUMAB; PERTUZUMAB; PONATINIB; RITUXIMAB; RUXOLITINIB; TRASTUZUMAB; VANDETANIB; VEMURAFENIB; VISMODEGIB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADENOMATOUS POLYP; BASAL CELL CARCINOMA; BREAST CANCER; CANCER GENETICS; CANCER TISSUE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DRUG INDICATION; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENOMICS; MELANOMA; MYELOFIBROSIS; NEOPLASM; NON SMALL CELL LUNG CANCER; NOTE; ONCOGENE; PRECANCER; SMALL CELL LUNG CANCER; THYROID MEDULLARY CARCINOMA; ANIMAL; CELL TRANSFORMATION; DRUG DESIGN; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC SCREENING; GENETICS; HUMAN; HUMAN GENOME; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PERSONALIZED MEDICINE; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DRUG DESIGN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; GENOME, HUMAN; HUMANS; MOLECULAR TARGETED THERAPY; PRECANCEROUS CONDITIONS; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS;

EID: 84908376880 PISSN: 19466234 EISSN: 19466242 Source Type: Journal
DOI: 10.1126/scitranslmed.3009148 Document Type: Note

Times cited : (11)

References (8)

1
- 84892833777
- Discovery and saturation analysis of cancer genes across 21 tumour types
- M. S. Lawrence, P. Stojanov, C. H. Mermel, J. T. Robinson, L. A. Garraway, T. R. Golub, M. Meyerson, S. B. Gabriel, E. S. Lander, G. Getz, Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
- (2014) Nature , vol.505 , pp. 495-501
- Lawrence, M.S.¹ Stojanov, P.² Mermel, C.H.³ Robinson, J.T.⁴ Garraway, L.A.⁵ Golub, T.R.⁶ Meyerson, M.⁷ Gabriel, S.B.⁸ Lander, E.S.⁹ Getz, G.¹⁰

2
- 84875490185
- Cancer genome landscapes
- B. Vogelstein, N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz Jr., K. W. Kinzler, Cancer genome landscapes. Science 339, 1546-1558 (2013).
- (2013) Science , vol.339 , pp. 1546-1558
- Vogelstein, B.¹ Papadopoulos, N.² Velculescu, V.E.³ Zhou, S.⁴ Diaz, L.A.⁵ Kinzler, K.W.⁶

3
- 77950809059
- A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
- S. V. Sharma, D. Y. Lee, B. Li, M. P. Quinlan, F. Takahashi, S. Maheswaran, U. McDermott, N. Azizian, L. Zou, M. A. Fischbach, K. K. Wong, K. Brandstetter, B. Wittner, S. Ramaswamy, M. Classon, J. Settleman, A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010).
- (2010) Cell , vol.141 , pp. 69-80
- Sharma, S.V.¹ Lee, D.Y.² Li, B.³ Quinlan, M.P.⁴ Takahashi, F.⁵ Maheswaran, S.⁶ McDermott, U.⁷ Azizian, N.⁸ Zou, L.⁹ Fischbach, M.A.¹⁰ Wong, K.K.¹¹ Brandstetter, K.¹² Wittner, B.¹³ Ramaswamy, S.¹⁴ Classon, M.¹⁵ Settleman, J.¹⁶

4
- 80755128256
- Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
- A. Becker, L. Crombag, D. A. Heideman, F. B. Thunnissen, A. W. van Wijk, P. E. Postmus, E. F. Smit, Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur. J. Cancer 47, 2603-2606 (2011).
- (2011) Eur. J. Cancer , vol.47 , pp. 2603-2606
- Becker, A.¹ Crombag, L.² Heideman, D.A.³ Thunnissen, F.B.⁴ Van Wijk, A.W.⁵ Postmus, P.E.⁶ Smit, E.F.⁷

5
- 84875758730
- Lessons from the cancer genome
- L. A. Garraway, E. S. Lander, Lessons from the cancer genome. Cell 153, 17-37 (2013).
- (2013) Cell , vol.153 , pp. 17-37
- Garraway, L.A.¹ Lander, E.S.²

6
- 0023748414
- Genetic alterations during colorectal-tumor development
- B. Vogelstein, E. R. Fearon, S. R. Hamilton, S. E. Kern, A. C. Preisinger, M. Leppert, Y. Nakamura, R. White, A. M. Smits, J. L. Bos, Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525-532 (1988).
- (1988) N. Engl. J. Med. , vol.319 , pp. 525-532
- Vogelstein, B.¹ Fearon, E.R.² Hamilton, S.R.³ Kern, S.E.⁴ Preisinger, A.C.⁵ Leppert, M.⁶ Nakamura, Y.⁷ White, R.⁸ Smits, A.M.⁹ Bos, J.L.¹⁰

7
- 0027197062
- Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
- F. M. Giardiello, S. R. Hamilton, A. J. Krush, S. Piantadosi, L. M. Hylind, P. Celano, S. V. Booker, C. R. Robinson, G. J. Offerhaus, Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328, 1313-1316 (1993).
- (1993) N. Engl. J. Med. , vol.328 , pp. 1313-1316
- Giardiello, F.M.¹ Hamilton, S.R.² Krush, A.J.³ Piantadosi, S.⁴ Hylind, L.M.⁵ Celano, P.⁶ Booker, S.V.⁷ Robinson, C.R.⁸ Offerhaus, G.J.⁹

8
- 84908388751
- note
- 9/L; no blood blasts; bone marrow blasts <5%; no extramedullary disease. These data were adapted from FDA prescribing information.

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.